WO2013022995A3 - Biomarker compositions and methods - Google Patents

Biomarker compositions and methods Download PDF

Info

Publication number
WO2013022995A3
WO2013022995A3 PCT/US2012/050030 US2012050030W WO2013022995A3 WO 2013022995 A3 WO2013022995 A3 WO 2013022995A3 US 2012050030 W US2012050030 W US 2012050030W WO 2013022995 A3 WO2013022995 A3 WO 2013022995A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
condition
stages
methods
biomarkers
Prior art date
Application number
PCT/US2012/050030
Other languages
French (fr)
Other versions
WO2013022995A2 (en
Inventor
Kirk Brown
Traci Pawlowski
David Spetzler
Original Assignee
Caris Life Sciences Luxembourg Holdings, S.A.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caris Life Sciences Luxembourg Holdings, S.A.R.L. filed Critical Caris Life Sciences Luxembourg Holdings, S.A.R.L.
Priority to CN201280049340.2A priority Critical patent/CN103874770A/en
Priority to AU2012294458A priority patent/AU2012294458A1/en
Priority to BR112014002975A priority patent/BR112014002975A2/en
Priority to KR1020147004204A priority patent/KR20140067001A/en
Priority to US14/237,793 priority patent/US20160041153A1/en
Priority to EP12821745.2A priority patent/EP2742154A4/en
Priority to JP2014525128A priority patent/JP2014522993A/en
Priority to CA2844671A priority patent/CA2844671A1/en
Publication of WO2013022995A2 publication Critical patent/WO2013022995A2/en
Publication of WO2013022995A3 publication Critical patent/WO2013022995A3/en
Priority to IL230868A priority patent/IL230868A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease, select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and to determine treatment efficacy. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles, and nucleic acid-protein complexes.
PCT/US2012/050030 2008-11-12 2012-08-08 Biomarker compositions and methods WO2013022995A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN201280049340.2A CN103874770A (en) 2011-08-08 2012-08-08 Biomarker compositions and methods
AU2012294458A AU2012294458A1 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods
BR112014002975A BR112014002975A2 (en) 2011-08-08 2012-08-08 biomarker compositions and methods
KR1020147004204A KR20140067001A (en) 2011-08-08 2012-08-08 Biomarker compositions and methods
US14/237,793 US20160041153A1 (en) 2008-11-12 2012-08-08 Biomarker compositions and markers
EP12821745.2A EP2742154A4 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods
JP2014525128A JP2014522993A (en) 2011-08-08 2012-08-08 Biomarker compositions and methods
CA2844671A CA2844671A1 (en) 2011-08-08 2012-08-08 Biomarker compositions and methods
IL230868A IL230868A0 (en) 2011-08-08 2014-02-06 Biomarker compositions and methods

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US201161521333P 2011-08-08 2011-08-08
US61/521,333 2011-08-08
US201161523763P 2011-08-15 2011-08-15
US61/523,763 2011-08-15
US201161526623P 2011-08-23 2011-08-23
US61/526,623 2011-08-23
US201161529762P 2011-08-31 2011-08-31
US61/529,762 2011-08-31
US201161534352P 2011-09-13 2011-09-13
US61/534,352 2011-09-13
US201161537462P 2011-09-21 2011-09-21
US61/537,462 2011-09-21
US201161542639P 2011-10-03 2011-10-03
US61/542,639 2011-10-03
US201161551674P 2011-10-26 2011-10-26
US61/551,674 2011-10-26
US201161559676P 2011-11-14 2011-11-14
US61/559,676 2011-11-14
US201261612111P 2012-03-16 2012-03-16
US61/612,111 2012-03-16
US201261619803P 2012-04-03 2012-04-03
US61/619,803 2012-04-03

Publications (2)

Publication Number Publication Date
WO2013022995A2 WO2013022995A2 (en) 2013-02-14
WO2013022995A3 true WO2013022995A3 (en) 2013-04-04

Family

ID=47669214

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/050030 WO2013022995A2 (en) 2008-11-12 2012-08-08 Biomarker compositions and methods

Country Status (8)

Country Link
EP (1) EP2742154A4 (en)
JP (1) JP2014522993A (en)
KR (1) KR20140067001A (en)
CN (1) CN103874770A (en)
AU (1) AU2012294458A1 (en)
BR (1) BR112014002975A2 (en)
CA (1) CA2844671A1 (en)
WO (1) WO2013022995A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US11971414B2 (en) * 2018-12-19 2024-04-30 Wisconsin Alumni Research Foundation Nanoengineered surfaces for cancer biomarker capture

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2294216A4 (en) 2008-05-14 2011-11-23 Dermtech Int Diagnosis of melanoma and solar lentigo by nucleic acid analysis
ES2720763T3 (en) 2012-06-27 2019-07-24 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
CN103160509B (en) * 2013-03-07 2015-02-18 新乡医学院第一附属医院 miRNA marker relative to esophagus cancer postoperative early relapse and prognosis and application
JP6554458B2 (en) * 2013-03-15 2019-07-31 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム MiRNA biogenesis in exosomes for diagnosis and therapy
CN104076151B (en) * 2013-03-29 2017-04-12 复旦大学附属华山医院 Kit for early diagnosis of glioma
AU2014261505B2 (en) * 2013-04-29 2019-04-18 Apogenix Ag Method of diagnosing cancer
EP2994545B1 (en) 2013-05-10 2019-03-20 University Of Southern California Dna methylation biomarkers for bladder cancer
BR112016002716B1 (en) * 2013-08-06 2023-02-28 Exosome Diagnostics, Inc METHOD FOR DIAGNOSING OR MONITORING PROGRESS OR RECURRENCE OF PROSTATE CANCER WITH HIGH GLEASON SCORE
JP2016533752A (en) * 2013-08-28 2016-11-04 カリス ライフ サイエンシズ スウィッツァーランド ホー Oligonucleotide probes and uses thereof
WO2015031604A1 (en) * 2013-08-28 2015-03-05 Crown Bioscience, Inc. Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
US10139402B2 (en) 2013-11-06 2018-11-27 Jsr Corporation Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy of disease treatment drug, kit, and liquid composition
FR3014198B1 (en) * 2013-12-03 2017-03-03 Biomerieux Sa METHOD FOR ISOLATING EXOSOMES
EP3078889B1 (en) * 2013-12-06 2019-09-18 The University of Tokyo Valve, fluid-controlling structure, fluid device, and method for manufacturing valve
WO2015103166A1 (en) * 2013-12-30 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
JP2017503169A (en) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド Diagnosis of systemic lupus erythematosus using oligonucleotide antigens
WO2015117164A1 (en) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders
WO2015165973A1 (en) 2014-04-29 2015-11-05 Apogenix Gmbh Diagnostic anti-cd95l antibody
AU2015252223A1 (en) * 2014-05-01 2016-11-24 Stichting Vumc Small ncRNAs as biomarkers
KR102510768B1 (en) 2014-06-12 2023-03-16 국립연구개발법인 고쿠리츠간켄큐센터 Prostate cancer detection kit or device, and detection method
ES2481819B1 (en) * 2014-06-12 2015-04-01 Sistemas Genómicos, S.L. ASSESSMENT METHOD TO EVALUATE A POSSIBILITY OF BREAST CANCER
US20160038608A1 (en) * 2014-08-07 2016-02-11 National Taiwan University Silica-based mesoporous carrier and delivery method of using the same
AU2014407088B2 (en) * 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
KR101596166B1 (en) 2014-10-07 2016-02-19 가톨릭대학교 산학협력단 A Use of microRNA for Ddiagnosing and Treating Brest Cancer
CN104313171A (en) * 2014-11-06 2015-01-28 南京大学 MicroRNA molecular marker for diagnosing glioma and application of microRNA molecular marker
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN105807063B (en) * 2014-12-29 2018-02-06 中国人民解放军第二军医大学 Applications of the CD63 in preparing diagnosis for liver disease kit or preparing prevention or treatment liver diseases medicine
CN104548134A (en) * 2015-01-04 2015-04-29 中国人民解放军第二军医大学 Application of miR-144 and inhibitor thereof
US20180148783A1 (en) * 2015-01-05 2018-05-31 The Johns Hopkins University Method of epigenetic analysis for determining clinical genetic risk
WO2016121821A1 (en) * 2015-01-27 2016-08-04 Jsr株式会社 Separation method, detection method, signal measurement method, method for determining disease, method for evaluating drug efficacy, kit, liquid composition, and analyte diluent
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170117450A (en) 2015-02-18 2017-10-23 엔리벡스 테라퓨틱스 리미티드 Combination of immunotherapy and cytokine regulating therapy for cancer treatment
CN107533058A (en) 2015-03-01 2018-01-02 免疫阵列有限公司 Use albumen, peptide and oligonucleotides diagnostic antigen systemic loupus erythematosus
WO2016145128A1 (en) 2015-03-09 2016-09-15 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN104714032B (en) * 2015-04-02 2015-09-16 闫星宇 For mark and the detection reagent thereof of postpartum eclampsia diagnosis
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3299816A4 (en) * 2015-05-20 2018-10-03 JSR Corporation Separation method, detection method, signal measurement method, disease determination method, drug efficacy assessment method, kit, liquid composition, and specimen diluent
AU2016275046B2 (en) 2015-06-10 2022-07-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CN104992058B (en) * 2015-06-25 2017-08-01 成都厚立信息技术有限公司 Disease risks adjust method for establishing model
CA2991045A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides binding c1q
CN105177117A (en) * 2015-07-03 2015-12-23 张理义 Major depressive disorder biomarker, screening method and kit
CN106350578A (en) * 2015-07-13 2017-01-25 中国人民解放军第二军医大学 Application of NY-ESO-1 in diagnosis and treatment of microsatellite instability intestinal cancer
WO2017019918A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
CN105039342B (en) * 2015-08-06 2017-12-01 李家平 SiRNA and its application of MAT2A gene expressions can be suppressed
WO2017025954A1 (en) * 2015-08-09 2017-02-16 Immunarray Ltd Methods for determining the risk of a systemic lupus erythematosus (sle) patient to develop neuropsychiatric syndromes
CN105067822B (en) * 2015-08-12 2017-05-24 中山大学附属肿瘤医院 Marker for diagnosing esophagus cancer
JP6583817B2 (en) * 2015-09-04 2019-10-02 国立大学法人山口大学 Diagnostic markers for tumors in uterine smooth muscle
KR102078310B1 (en) * 2015-09-11 2020-02-19 주식회사 압타머사이언스 Protein biomarker panel for diagnosing non-small cell lung cancer and method for diagnosing non-small cell lung cancer using the same
BR112018005175A2 (en) 2015-09-17 2018-10-16 Amgen Inc prediction of clinical response to il23 antagonists using il23 pathway biomarkers
EP3165926A1 (en) * 2015-11-06 2017-05-10 Humanitas Mirasole S.p.A. Method for characterization of cell specific microvesicles
US11230735B2 (en) 2015-12-24 2022-01-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Systems and methods for characterizing sepsis
WO2017113565A1 (en) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 Kit for auxiliary diagnosis of patient with liver cancer or digestive tract cancer based on protein marker psg3
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
CN109715802A (en) 2016-03-18 2019-05-03 卡里斯科学公司 Oligonucleotide probe and application thereof
CN105842461A (en) * 2016-04-30 2016-08-10 广州恒泰生物科技有限公司 Rapid diagnostic kit for uterine sarcoma in early and middle stages and preparation method of kit
WO2017205686A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN107475356A (en) * 2016-06-08 2017-12-15 益善生物技术股份有限公司 Osteosarcoma circulating tumor cell identification kit
CN105907875A (en) * 2016-06-13 2016-08-31 武汉泰安康生物科技有限公司 Method for screening kidney cancer peripheral blood miRNA marker and kidney cancer marker miR-378
JP6980219B2 (en) * 2016-08-22 2021-12-15 いであ株式会社 How to detect cancer or determine the stage of cancer staging
WO2018091419A1 (en) * 2016-11-15 2018-05-24 Ventana Medical Systems, Inc. Compositions and methods for prognosing and treating colorectal cancer
CN108165635B (en) * 2016-12-07 2021-07-13 南京农业大学 KIAA1462 gene promoter region variant site and application thereof in improving egg laying performance of geese
US20210072255A1 (en) 2016-12-16 2021-03-11 The Brigham And Women's Hospital, Inc. System and method for protein corona sensor array for early detection of diseases
DE202017107858U1 (en) * 2016-12-16 2018-05-28 The Brigham And Women's Hospital, Inc. Device for a protein corona sensor array for the early detection of diseases
CN106636296A (en) * 2016-12-22 2017-05-10 广州医科大学附属肿瘤医院 Application of Hsp27 in tolerance diagnosis and treatment for tongue cancer chemotherapy
CN106501517B (en) * 2016-12-27 2018-05-08 北京蛋白质组研究中心 Detect application of the material of SPARC protein in serum in examination hepatocellular carcinoma kit is prepared
CN106939340A (en) * 2017-03-31 2017-07-11 哈尔滨医科大学 A kind of molecular marked compound related to adenocarcinoma of lung transfer and prognosis and its application
CN106947820B (en) * 2017-04-11 2020-09-29 成都望路医药技术有限公司 Application of VCAN in diagnosis and treatment of colon adenocarcinoma
CA3062858A1 (en) 2017-05-12 2018-11-15 The Regents Of The University Of Michigan Individual and cohort pharmacological phenotype prediction platform
CN106987649A (en) * 2017-05-31 2017-07-28 上海博慷生物科技有限公司 A kind of primer sets and detection method for being used to detect glioma
CN109085355A (en) * 2017-06-13 2018-12-25 中国医学科学院肿瘤医院 Serum protein markers combine the application in screening lung cancer and diagnosis and treatment
CN107273718A (en) * 2017-06-27 2017-10-20 电子科技大学 A kind of Analysis of Survival Time method of fusion dna methylation characteristic
JP7029719B2 (en) * 2017-08-31 2022-03-04 静岡県 Biomarker
CN107630092B (en) * 2017-10-23 2020-03-31 广州医科大学附属第二医院 Application of miR-505-3p in diagnosis, prognosis and treatment of bone metastasis of prostate cancer
CN107868829B (en) * 2017-12-26 2021-05-18 浙江自贸区锐赛生物医药科技有限公司 Combined reagent and kit for evaluating postoperative recurrence risk of chordoma and application of combined reagent and kit
CN107937621A (en) * 2018-01-12 2018-04-20 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） The application of miRNA, product and detection method using it
CN108192970A (en) * 2018-01-24 2018-06-22 苏州大学 A kind of diagnosing cancer of liver marker and its application
CN108048460B (en) * 2018-02-01 2021-04-09 浙江大学 Novel molecular marker and application thereof in preparation of kit for head and neck cancer diagnosis and prognosis
US11681953B2 (en) 2018-04-13 2023-06-20 Freenome Holdings, Inc. Machine learning implementation for multi-analyte assay development and testing
FR3080185A1 (en) * 2018-04-16 2019-10-18 Biomerieux EVALUATION OF THE RISK OF COMPLICATION IN A PATIENT SUSPECTED TO HAVE AN INFECTION HAVING A SOFA SCORE LESS THAN TWO
CN108559778B (en) * 2018-04-28 2020-06-12 北京师范大学 Multiple myeloma molecular typing and application thereof in medication guidance
CN108570501B (en) * 2018-04-28 2020-06-12 北京师范大学 Multiple myeloma molecular typing and application
CN108586579B (en) * 2018-05-11 2021-11-30 京东方科技集团股份有限公司 Quasi-peptide, derivative, salt, preparation method and application thereof
CN113855675A (en) * 2018-05-22 2021-12-31 郑州大学第一附属医院 Kit and medicine based on gallbladder cancer marker
CN108841962B (en) * 2018-08-01 2021-11-19 博奥生物集团有限公司 Non-small cell lung cancer detection kit and application thereof
KR102094608B1 (en) * 2018-08-08 2020-04-23 고려대학교 산학협력단 Method for Providing Information on Classification and Prognosis of Hematologic Malignancy
US11535899B2 (en) 2018-08-10 2022-12-27 Toray Industries, Inc. Kit, device and method for detecting prostate cancer
CN109321656B (en) * 2018-10-22 2021-10-01 上海交通大学医学院附属仁济医院 Use of protein DEPDC1 as marker for diagnosing triple-negative breast cancer
EP3875585A4 (en) * 2018-11-01 2022-11-16 Kao Corporation Method for preparing nucleic acid derived from skin cell of subject
WO2020096631A2 (en) 2018-11-07 2020-05-14 Seer, Inc. Compositions, methods and systems for protein corona analysis and uses thereof
CN109507425A (en) * 2018-11-07 2019-03-22 国家纳米科学中心 Carcinoma of prostate based on the extracellular vesica of thermophoresis recurs monitoring system and method
WO2020104588A1 (en) * 2018-11-22 2020-05-28 Institut D'investigació Sanitària Pere Virgili Biomarkers of prostate cancer aggressiveness
CN109609630B (en) * 2018-12-03 2023-01-13 哈尔滨医科大学 Molecular marker for early gastric cancer diagnosis and application thereof
CN109439757A (en) * 2018-12-18 2019-03-08 首都医科大学附属北京佑安医院 Application of the blood plasma excretion body miR-455-3p as early liver cancer diagnosis marker
CN109652504B (en) * 2018-12-27 2021-03-16 杭州迪相实业有限公司 Method for simultaneously detecting exosome membrane protein and mRNA
JP2022517563A (en) * 2019-01-02 2022-03-09 チョーチアン クラウンマブ バイオテック カンパニー リミテッド Treatment of cancer with multi-target kinase inhibitors in combination with protein kinase biomarkers
CN109609653B (en) * 2019-02-12 2019-07-19 山东大学齐鲁医院 The molecular marked compound and its application of diagnosis or treatment glioma
EP3699300A1 (en) * 2019-02-22 2020-08-26 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Seminal mirnas as non-invasive biomarkers for the diagnosis and/or prognosis of prostate cancer
WO2020198229A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
CN110196329A (en) * 2019-05-31 2019-09-03 郑州大学第一附属医院 A kind of cancer of the esophagus early stage combined detection kit
WO2020262374A1 (en) * 2019-06-27 2020-12-30 コニカミノルタ株式会社 Exosome measurement method and exosome measurement kit
CN110279707A (en) * 2019-07-05 2019-09-27 深圳市康宁医院(深圳市精神卫生研究所深圳市精神卫生中心) MiR-212 is preparing the application in the drug for treating habituation
WO2021013479A1 (en) * 2019-07-19 2021-01-28 Universiteit Antwerpen Mucin isoforms in diseases characterized by barrier dysfunction
KR102346864B1 (en) * 2019-07-24 2022-01-04 한국전자기술연구원 Biomarker composition for diagnosing or prognostic analysis of bladder cancer, kit comprising the same and method for diagnosing bladder cancer using the same
CN110295228A (en) * 2019-08-05 2019-10-01 中国人民解放军总医院第八医学中心 Detect application of the substance of GATA2 in preparation diagnostic activities kit lungy
WO2021026172A1 (en) 2019-08-05 2021-02-11 Seer, Inc. Systems and methods for sample preparation, data generation, and protein corona analysis
CN110551809A (en) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 Application of miR-124 in spinal cord injury repair
CN110564867B (en) * 2019-10-10 2022-06-24 扬州大学 SNP molecular marker of Qinchuan cattle CFL1 gene and detection method thereof
CN110643672A (en) * 2019-10-15 2020-01-03 西安交通大学 Medical application of high-expression TrkB as novel target point in inhibiting pancreatic cancer metastasis
CN115244149B (en) * 2019-12-27 2023-09-15 关西涂料株式会社 Paint manufacturing method, color data prediction method and computer color matching system
CN111647658B (en) * 2020-06-05 2022-09-27 上海市第一人民医院 Application of LINC00963 related oncogenic axis in early diagnosis and treatment of prostate cancer distant metastasis
CN111690746A (en) * 2020-06-30 2020-09-22 镇江维思生物科技有限责任公司 Platelet RNA marker related to lung cancer and application thereof
CN113940999B (en) * 2020-07-15 2022-11-29 中国农业大学 Application of target point for treating non-alcoholic fatty liver disease
CN112180100A (en) * 2020-09-27 2021-01-05 西安交通大学 Application of TWEAK as molecular marker for identifying different types of psoriasis
CN112255408B (en) * 2020-10-16 2023-04-14 牡丹江医学院 Tumor biomarker and tumor detection kit
CN112285195B (en) * 2020-10-27 2021-08-10 江南大学 Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome
CN112433053A (en) * 2020-11-20 2021-03-02 四川大学华西医院 Application of Tetraspin-14 protein detection reagent in preparation of lung cancer screening kit
CN112301133B (en) * 2020-12-01 2021-07-27 江门市中心医院 Application of cholesterol generation gene label in prognosis prediction of young breast cancer patient
KR102427057B1 (en) * 2020-12-04 2022-07-29 전남대학교산학협력단 Biomaker for metastasis prediction or prognosis analysis of Solitary fibrous tumor/hemangiopericytoma and diagnosis method using there of
WO2022133621A1 (en) 2020-12-24 2022-06-30 Pontificia Universidad Católica De Chile In-vitro method for diagnosing and predicting the aggressiveness of thyroid cancer, and the precision surgery options and type to be used to remove a tumour from a patient; kit; reagents forming the kit; and use of the reagents and use of molecular markers as part of the method
CN113151460B (en) * 2021-01-29 2022-10-18 复旦大学附属中山医院 Gene marker for identifying lung adenocarcinoma tumor cells and application thereof
CN115166245A (en) * 2021-04-04 2022-10-11 兰州大学第一医院 Application of CLU (CLU) and composition thereof in diagnosis of bile duct cancer and bile duct cancer diagnosis kit
KR102540416B1 (en) * 2021-04-09 2023-06-12 주식회사 애티스랩 Composition or kit for diagnosing cancer and method for diagnosis cancer
CN113125757B (en) * 2021-04-22 2022-10-28 石河子大学 Protein biomarker for early pregnancy diagnosis of sows and method for detecting early pregnancy of sows by using protein biomarker
CN113122544A (en) * 2021-04-25 2021-07-16 杭州广科安德生物科技有限公司 Aptamer specifically binding with TIMP1 protein and application thereof
CN113311166B (en) * 2021-04-28 2022-10-28 新疆农垦科学院 Protein biomarker for diagnosing early pregnancy of sheep and method for detecting early pregnancy of sheep
CN113186267A (en) * 2021-06-07 2021-07-30 上海康黎诊断技术有限公司 Primer-probe combination, kit and method for detecting human CYP2D6 copy number variation and genotyping
CN113687076B (en) * 2021-07-14 2024-03-01 郑州大学 Combined detection serum marker for early diagnosis of lung adenocarcinoma and application thereof
GB202111635D0 (en) * 2021-08-13 2021-09-29 Randox Laboratories Risk prediction model for prostate cancer
WO2023054436A1 (en) * 2021-09-29 2023-04-06 株式会社西尾 Beauty method
WO2023064883A1 (en) * 2021-10-14 2023-04-20 The University Of Chicago Immunotherapeutic methods for treating cancer
WO2023140658A1 (en) * 2022-01-24 2023-07-27 고려대학교 산학협력단 Pharmaceutical composition for diagnosing, preventing or treating sepsis by using brain-derived neurotrophic factor
WO2023169686A1 (en) * 2022-03-10 2023-09-14 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer
WO2024050856A1 (en) * 2022-09-06 2024-03-14 南京市第一医院 Method and system for assisting blood cell analyzer in determining abnormal platelet aggregation

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038207A1 (en) * 1999-02-22 2004-02-26 Orntoft Torben F. Gene expression in bladder tumors
US20050152908A1 (en) * 2003-11-03 2005-07-14 Genenews Inc. Liver cancer biomarkers
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20090203533A1 (en) * 2005-07-08 2009-08-13 Siemens Medicals Solutions Diagnositcs Gmbh Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
US20100248290A1 (en) * 2007-11-23 2010-09-30 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US20100248225A1 (en) * 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20110151460A1 (en) * 2008-11-12 2011-06-23 Caris Life Sciences Luxembourg Holdings a Luxembourg corporation Methods and systems of using exosomes for determining phenotypes
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
US20110177054A1 (en) * 2008-06-06 2011-07-21 Derrick Gibbings Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641010A (en) * 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 Be used as the modification of the allochthon component of vaccine
CA2676113C (en) * 2007-07-25 2014-07-08 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
US8617806B2 (en) * 2008-01-25 2013-12-31 Hansabiomed Ou Method to measure and characterize microvesicles in the human body fluids
CN102308004A (en) * 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 Methods for assessing RNA patterns
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
AU2010324594B2 (en) * 2009-11-30 2016-09-15 Caris Life Sciences Switzerland Holdings Gmbh Methods and systems for isolating, storing, and analyzing vesicles

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038207A1 (en) * 1999-02-22 2004-02-26 Orntoft Torben F. Gene expression in bladder tumors
US20050152908A1 (en) * 2003-11-03 2005-07-14 Genenews Inc. Liver cancer biomarkers
US20090203533A1 (en) * 2005-07-08 2009-08-13 Siemens Medicals Solutions Diagnositcs Gmbh Methods and Kits for Predicting and Monitoring Direct Response to Cancer Therapy
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100248225A1 (en) * 2006-11-06 2010-09-30 Bankaitis-Davis Danute M Gene expression profiling for identification, monitoring and treatment of melanoma
US20100248290A1 (en) * 2007-11-23 2010-09-30 British Columbia Cancer Agency Branch Methods for detecting lung cancer and monitoring treatment response
US20110177054A1 (en) * 2008-06-06 2011-07-21 Derrick Gibbings Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna
US20110151460A1 (en) * 2008-11-12 2011-06-23 Caris Life Sciences Luxembourg Holdings a Luxembourg corporation Methods and systems of using exosomes for determining phenotypes
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US11971414B2 (en) * 2018-12-19 2024-04-30 Wisconsin Alumni Research Foundation Nanoengineered surfaces for cancer biomarker capture

Also Published As

Publication number Publication date
CA2844671A1 (en) 2013-02-14
WO2013022995A2 (en) 2013-02-14
EP2742154A2 (en) 2014-06-18
EP2742154A4 (en) 2015-08-12
CN103874770A (en) 2014-06-18
KR20140067001A (en) 2014-06-03
JP2014522993A (en) 2014-09-08
BR112014002975A2 (en) 2017-03-01
AU2012294458A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
WO2013022995A3 (en) Biomarker compositions and methods
WO2013134786A3 (en) Biomarker compositions and methods
WO2012174282A3 (en) Biomarker compositions and methods
WO2014193999A3 (en) Biomarker methods and compositions
BR112013031591A2 (en) circulation biomarkers for cancer
WO2010056337A3 (en) Methods and systems of using exosomes for determining phenotypes
BR112012025593A2 (en) circulating biomarkers for disease
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
MX346096B (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
WO2013033074A3 (en) Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use
WO2012021407A3 (en) Biomarkers for stroke
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2013068373A3 (en) Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
BR112013023722A2 (en) methods for predicting the risk of an individual having or developing a disease, and for diagnosing an individual with a disease, kit, nonhuman animal model, and system for identifying aberrant coriocapillary lobes
WO2012135844A3 (en) Circulating exosomes as diagnostic/prognostic indicators and therapeutic targets of melanoma and other cancers
WO2010091049A3 (en) Diagnosis and treatment of cancer
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
WO2011156734A3 (en) Method of characterizing vascular diseases
WO2018037229A8 (en) Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers
WO2012112315A3 (en) Methods for diagnosis of kawasaki disease
BR112014031414A2 (en) methods of detecting disease or conditions using circulating diseased cells
WO2014004889A3 (en) Plasma analytes predict diagnosis and prognosis of thoracic aortic aneurysm
EA201490105A1 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF KIDNEY DAMAGE AND RENAL FAILURE
WO2013159872A8 (en) Biomarkers for the diagnosis, prognosis, assessment and therapy stratification of syncope

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12821745

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 230868

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2844671

Country of ref document: CA

Ref document number: 2014525128

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20147004204

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012294458

Country of ref document: AU

Date of ref document: 20120808

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12821745

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014002975

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 14237793

Country of ref document: US

ENP Entry into the national phase

Ref document number: 112014002975

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140207